Laparoscopic Bilateral Transperitoneal Adrenalectomy For Cushing Syndrome

Surgical Laparoscopy, Endoscopy & Percutaneous Techniques, 07/16/2013  Clinical Article

Aggarwal S et al. –

Laparoscopic adrenalectomy is well established for treatment of adrenal lesions. However, bilateral adrenalectomy for Cushing syndrome is a challenging and time–consuming operation.

The authors report their experience of laparoscopic bilateral adrenalectomy for this disease in 19 patients. Laparoscopic bilateral adrenalectomy for Cushing syndrome is feasible and safe. It confers all the advantages of minimally invasive approach such as less postoperative pain, shorter hospitalization, lesser wound complications, and faster recovery.

The advantages of the laparoscopic approach have led to an earlier referral for bilateral adrenalectomy by endocrinologist in patients with failed pituitary surgery.

 

This article is available on PubMed

Upcoming Endocrinology Conferences

73rd Scientific Sessions (2013) of American Diabetes Association CME 
June 21-25, 2013 -Chicago, Illinois, United States

6th International Conference on Childrens Bone Health CME 
June 22-25, 2013 -Rotterdam, Netherlands

2013 Annual Meeting of the Society for Behavioral Neuroendocrinology CME 
June 23-26, 2013 -Atlanta, Georgia, United States

17th Annual Conference on Hypertension – Focus on Hypertension, Diabetes and Dyslipidemia CME 
June 28-30, 2013 -Charleston, South Carolina, United States

Bone Densitometry Comprehensive Exam Review CME 
August 3, 2013 -Houston, Texas, United States

4th World Congress on Diabetes & Metabolism CME 
August 14-16, 2013 -Skokie, Illinois, United States

Anti-Aging Medicine: Advances in Hormone Replacement CME 
August 17-18, 2013 -Chicago, Illinois, United States

World Congress on Endocrinology 2013 CME 
August 26-28, 2013 -Raleigh, North Carolina, United States

HBPR 2013: High Blood Pressure Research 2013 Scientific Sessions CME 
September 11-14, 2013 -New Orleans, Louisiana, United States

35th Annual British Andrology Society Meeting CME 
September 13-14, 2013 -Liverpool, United Kingdom

5th Florence-Utah Symposium on Genetics of Male Infertility 
September 19-21, 2013 -Florence, Italy

2013 Cardiometabolic Health Congress CME 
October 2-5, 2013 -Boston, Massachusetts, United States

Bone Densitometry: Principles and Procedures CME 
October 5-6, 2013 -Houston, Texas, United States

11th Annual Meeting of Androgen Excess & PCOS Society CME 
October 17-18, 2013 -Newport, Rhode Island, United States

AAES 2014 Annual Meeting CME 
April 27-29, 2014 -Boston, Massachusetts, United States

74th Scientific Sessions of American Diabetes Association CME 
June 13-17, 2014 -San Francisco, California, United States

50th EASD Annual Meeting CME 
September 15-19, 2014 -Vienna, Austria

84th Annual Meeting of the American Thyroid Association CME 
October 29 – November 2, 2014 -Coronado, California, United States

ENDO 2015 CME 
March 5-8, 2015 -San Diego, California, United States

AAES 2015 Annual Meeting CME 
May 17-19, 2015 -Nashville, Tennessee, United States

Exophthalmos: A Forgotten Clinical Sign of Cushing’s Syndrome

Case Reports in Endocrinology
Volume 2013 (2013), Article ID 205208, 3 pages
http://dx.doi.org/10.1155/2013/205208
Case Report

Exophthalmos: A Forgotten Clinical Sign of Cushing’s Syndrome

1Department of Internal Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue Desk NA10, Cleveland, OH 44195, USA
2Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic Foundation, 9500 Euclid Avenue Desk F20, Cleveland, OH 44195, USA

Received 3 February 2013; Accepted 22 February 2013

Academic Editors: C. Capella, T. Cheetham, M. Demura, and K. Iida

Copyright © 2013 Aldo Schenone Giugni et al. This is an open access article distributed under theCreative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Exophthalmos is typically associated with Graves’ ophthalmopathy. Although originally described by Harvey Cushing, exophthalmos is an underappreciated sign of Cushing’s syndrome. We present a case of a 38-year-old female who presented with severe bilateral proptosis and was subsequently diagnosed with Cushings disease. We discuss the possible mechanisms causing exophthalmos in patients with either endogenous or exogenous hypercortisolemia.

1. Case Presentation

A 38-year-old female noticed progressively worsening bilateral proptosis for a period of two years, to the point causing episodes of ocular dislocation from her sockets. She also noted irregular menstrual cycles during this time and was amenorrheic for 6 months prior to referral. She underwent extensive workup by her primary care physician including thyroid tests which were normal. She then underwent orbital decompression surgery in June 2011 with transient improvement of symptoms. However in the next 12 months she gained 60 lbs and developed proximal muscle weakness, purplish abdominal striae, facial hirsutism, and easy bruisability. She was also diagnosed with new onset diabetes and hypertension during this time and was treated with Metformin and Lisinopril, respectively. Physical examination revealed an obese female with a BMI of 43 and BP . She had frank stigmata of Cushings syndrome (CS). She had bilateral proptosis with Hertel’s exophthalmometry readings of 26 mm (right) and 27 mm (left) (Figure 1). Visual acuity was  bilaterally. There was no corneal/conjunctival congestion or lid retraction/lag. Fundus exam was normal. Extraocular movements were intact and visual fields were normal on confrontation. Tonometry was not performed. Labs done prior to referral indicated midnight salivary cortisol of 654 ng/dL (normal 112 ng/dL) and post 1 mg dexamethasone cortisol of 16.9 mcg/dL. Random ACTH level was 50 (8–42 pg/mL). MRI of pituitary gland revealed 1.6 cm macroadenoma with deviation of the stalk to the right (Figure 2). MRI also indicated bilateral exophthalmos with increased retrorbital fat (Figure 2). Prolactin was 40 (2–17.4 ng/mL) consistent with stalk effect, gonadotropins were low, and IGF-1, free T4 were normal. Patient underwent trans-sphenoidal removal of the tumor which stained diffusely with ACTH (Figure 3). Patient is being treated with hydrocortisone and followed closely by her ophthalmologist. Although the exophthalmos persisted after the pituitary surgery, episodes of ocular dislocation had not occurred at 3 months followup.

205208.fig.001
Figure 1: Bilateral exophthalmos as seen on MRI.
205208.fig.002
Figure 2: MRI of pituitary (coronal view) (arrows showing the macroadenoma and stalk deviation).
fig3
Figure 3: Histology: (a) H&E stain showing basophilic cells at magnification 200. (b) Positive ACTH staining.

2. Discussion

Exophthalmos or proptosis refers to forward displacement of the eyeball. It has to be differentiated from retraction of the eyelids, which can cause an illusion of exophthalmos. Conventionally, exophthalmos refers to ocular proptosis secondary to endocrinopathies. Graves’ disease is the most common endocrine cause of exophthalmos. Although described in 1932 by Harvey Cushing in 4 of his 12 patients with Cushings disease, this is an often forgotten clinical sign [1] in patients with CS. We have presented a case highlighting the importance of exophthalmos and its association with hypercortisolemia.

Exophthalmos is seen in about 30–45% of patients with Cushings syndrome (CS) [13]. Kelly reported that exophthalmos (exceeding 16 mm) occurred in 45% of active CS, 21% of iatrogenic CS, and 20% of treated CS in comparison to 2% in controls [3]. Cases of severe exophthalmos preceding the evolution of CS have been reported in the literature [45].

The cause of exophthalmos in CS is still unknown. Multiple theories have been proposed including fat redistribution and increased retro-orbital fat, associated thyroid disease, and an exophthalmos causative factor. It has been proposed that retro-orbital fat deposition is also part of the fat re-distribution seen in CS, resulting in increase in volume of the retro-orbital tissues and a consequent rise in intra-orbital pressure [36]. Orbital fat volume was increased in patients with CS and orbital muscles are relatively spared [78]. In contrast to patients with Graves’ disease the retrorbital fat in CS is devoid of inflammatory cell infiltration. Whether differential fat deposition in the orbits is due to increased glucocorticoid receptor density, defective lipolysis or increased lipoprotein lipase activity is not known.

Conflict of Interests

The authors report no conflict of interests.

References

  1. H. Cushing, “The basophil adenomas of the pituitary body and their clinical manifestation,”Bulletin Johns Hopkins Hospital, vol. 50, pp. 173–195, 1932.
  2. T. A. Howlett, L. H. Rees, and G. M. Besser, “Cushing’s syndrome,” Clinics in Endocrinology and Metabolism, vol. 14, no. 4, pp. 911–945, 1985. View at Scopus
  3. W. Kelly, “Exophthalmos in cushing’s syndrome,” Clinical Endocrinology, vol. 45, no. 2, pp. 167–170, 1996.
  4. M. Nezu, I. Miwa, K. Minai, and T. Kagami, “A case of Cushing’s syndrome associated with severe exophthalmos,” Nihon Naika Gakkai, vol. 76, no. 8, pp. 1290–1293, 1987. View at Scopus
  5. A. Boschi, M. Detry, T. Duprez et al., “Malignant bilateral exophthalmos and secondary glaucoma in iatrogenic Cushing’s syndrome,” Ophthalmic Surgery and Lasers, vol. 28, no. 4, pp. 318–320, 1997. View at Scopus
  6. S. W. Panzer, J. R. Patrinely, and H. K. Wilson, “Exophthalmos and iatrogenic Cushing’s syndrome,” Ophthalmic Plastic and Reconstructive Surgery, vol. 10, no. 4, pp. 278–282, 1994.View at Scopus
  7. R. G. Peyster, F. Ginsberg, J. H. Silber, and L. P. Adler, “Exophthalmos caused by excessive fat: CT volumetric analysis and differential diagnosis,” American Journal of Roentgenology, vol. 146, no. 3, pp. 459–464, 1986. View at Scopus
  8. G. Forbes, D. G. Gehring, C. A. Gorman, M. D. Brennan, and I. T. Jackson, “Volume measurements of normal orbital structures by computed tomographic analysis,” American Journal of Roentgenology, vol. 145, no. 1, pp. 149–154, 1985. View at Scopus

From http://www.hindawi.com/crim/endocrinology/2013/205208/

New Endocrinology App

[prMac.com] South Dartmouth, Massachusetts – The Editors of Endotext and Thyroidmanager announce the release of their new medical app, “Endocrinology and Endo Emergency”.

The app provides concise, practical information on endocrine emergencies, and provides the answers needed RIGHT NOW for their care. Each of the 36 topics covered includes the clinical recognition, pathophysiology, diagnosis, differential, treatment, and follow up. In addition, references to available Clinical Guidelines, and important literature citations are provided.

Focusing on the critical information needed at the point of care, the app includes topics such as Cushing’s disease, diabetic ketoacidosis, managing acute type I and type II diabetes, hypercholesterolemia, adrenal insufficiency, hyperthyroidism, thyroid storm, and much more. Key facts are presented in tables and flow-charts to allow quick reference to crucial information.

The app is designed for physicians, nurses, emergency room caregivers, hospitalists, trainees, students, and any caregiver who needs to treat seriously ill patients.

The “Endocrinology and Endo Emergency” mobile application was created by the world-renowned endocrinologists who also brought you ENDOTEXT.ORG and THYROIDMANAGER.ORG, the most comprehensive and up-to-date web-based endocrine textbooks. Endocrinology and Endo Emergency is always updated with the latest information, and updates can be automatically downloaded by users.

To view or purchase the app in the Apple App store (also available for android) or go to endoemergencies website for information and to view a sample section. Qualified reviewers may contact us for promo codes.

* Covers endocrinology and endocrine emergencies

* Provides critical information needed at the point of care

* 36 topics covered

* written by expert endocrinologists from around the world

Device Requirements:
* iPhone 3GS, iPhone 4, iPhone 4S, iPod touch (3rd generation), iPod touch (4th generation) and iPad
* Requires iOS 5.0 or later
* 1.7 MB

 

Pricing and Availability:
Endocrinology & Endo Emergency 1.0 is $5.99 USD (or equivalent amount in other currencies) and available worldwide exclusively through the App Store in the Medical category.

Endocrine Emergencies
Thyroid Disease Manager
Endotext Web Book
Purchase and Download
Screenshot
App Icon

Produced and owned by Endocrine Education, Inc. and Mdtext.Com, Inc. Copyright (C) 2012 Endocrine Education, Inc. and Mdtext.Com, Inc. All Rights Reserved. Apple, the Apple logo, iPhone, iPod and iPad are registered trademarks of Apple Inc. in the U.S. and/or other countries.

From http://prmac.com/release-id-38000.htm

NIH Cushing’s Clinical Trials

Rank Status Study
1 Recruiting Safety and Efficacy of LCI699 in Cushing’s Disease Patients

Condition: Cushing Disease
Intervention: Drug: LCI699
2 Recruiting Preoperative Bexarotene Treatment for Cushing’s Disease

Condition: Cushing’s Disease
Intervention: Drug: Bexarotene
3 Recruiting Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: rosiglitazone maleate;   Other: laboratory biomarker analysis
4 Unknown  Study of Depression, Peptides, and Steroids in Cushing’s Syndrome

Condition: Cushing’s Syndrome
Intervention:
5 Recruiting Examination of Brain Serotonin Receptors in Patients With Mood Disorders

Conditions: Mood Disorder;   Bipolar Disorder;   Depression
Intervention:
6 Recruiting An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

Conditions: Abnormalities;   Craniopharyngioma;   Cushing’s Syndrome;   Endocrine Disease;   Pituitary Neoplasm
Intervention:
7 Recruiting Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing’s Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion

Condition: Cushing’s Syndrome
Intervention: Drug: Mifepristone
8 Recruiting Anesthesia Management of Retroperitoneal Adrenalectomies

Condition: Adrenal Tumors
Intervention:
9 Recruiting Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex

Conditions: Cushing’s Syndrome;   Hereditary Neoplastic Syndrome;   Lentigo;   Neoplasm;   Testicular Neoplasm
Intervention:
10 Recruiting New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome

Condition: Cushing Syndrome
Intervention:
11 Recruiting Adolescence, Puberty, and Emotion Regulation

Conditions: Mood Disorder;   Neurobehavioral Manifestation;   Healthy
Intervention:
12 Recruiting Insulin Sensitivity and Substrate Metabolism in Patients With Cushing’s Syndrome

Conditions: Cushing’s Syndrome;   Insulin Resistance
Intervention: Procedure: Surgery
13 Recruiting Study of Adrenal Gland Tumors

Condition: Adrenal Gland Neoplasm
Intervention:
14 Not yet recruiting Adrenalectomy Versus Follow-up in Patients With Subclinical Cushings Syndrome

Condition: Adrenal Tumour With Mild Hypercortisolism
Intervention: Procedure: Adrenalectomy
15 Recruiting Assessing Fertility Potential in Female Cancer Survivors

Condition: History of Cancer
Intervention:
16 Recruiting Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Conditions: Pancreatic Neoplasm;   Pituitary Neoplasm;   Nelson Syndrome;   Ectopic ACTH Syndrome
Intervention: Drug: Pasireotide LAR
17 Recruiting Adrenal Tumors – Pathogenesis and Therapy

Conditions: Adrenal Tumors;   Adrenocortical Carcinoma;   Cushing Syndrome;   Conn Syndrome;   Pheochromocytoma
Intervention:
18 Recruiting Prevalence of Pituitary Incidentaloma in Relatives of Patients With Pituitary Adenoma

Condition: Pituitary Tumor
Intervention:
19 Recruiting Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)

Conditions: Neutropenia;   Infection
Interventions: Drug: Standard antimicrobial therapy;   Biological: Granulocyte transfusions;   Drug: G-CFS/dexamethasone;   Device: Apheresis machine